Newswise — In a new SLAS Technology auto-commentary, two authors of an article recently published in Nature Biomedical Engineering (“Abnormal Scar Identification with Spherical Nucleic Acid Technology” – www.nature.com/articles/s41551-018-0218-x) share more insight into their unique method for skin disease diagnosis using NanoFlare nanotechnology. In particular, the authors address point-of-care diagnosis and image acquisition, which are the primary bottlenecks in efficient disease diagnosis.
Authors David Yeo, Ph.D., and Prof. Chenjie Xu, Ph.D., of the School of Chemical and Biomedical Engineering at Nanyang Technological University (Singapore) use NanoFlare to enable biopsy-free disease diagnosis and progression monitoring in response to therapy. It is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden.
This vision of simplifying disease diagnosis using topically-applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed.
Simplifying Skin Disease Diagnosis with Topical Nanotechnology can be accessed for free for a limited time at http://journals.sagepub.com/doi/full/10.1177/2472630318775314. For more information about SLAS and its journals, visit www.slas.org/journals.
A PDF of this article is available to credentialed media outlets upon request. Contact firstname.lastname@example.org.
About our Society and Journals
SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).
SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).
Follow SLAS on Twitter at @SLAS_Org.
Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.
Follow SLAS on YouTube at SLASvideo.
Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).
Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).